Method for reducing the immunogenicity of antibody variable domains
CA 2068593 C · Owner: Merck & Co. Inc. · Inventors: Daugherty, Bruce L.; Padlan, Eduardo A.; Mark, George E. Iii
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 13, 1992 and granted July 8, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 13, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 13, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.